Guj. Terce Labs.

Why is Gujarat Terce Laboratories Ltd falling/rising?

As of 28-Jun, Gujarat Terce Laboratories Ltd's stock price is at Rs 34.44, reflecting a 5.62% decline. The stock has significantly underperformed the market, with a year-to-date drop of 20.83% and a notable decrease in investor participation.

As of 28-Jun, Gujarat Terce Laboratories Ltd's stock price is falling, currently at Rs 34.44, which reflects a decrease of Rs 2.05 or 5.62%. This decline is evident in the stock's performance over various periods, including a 5.20% drop over the past week, a 2.13% decrease over the past month, and a significant 20.83% decline year-to-date. Over the past year, the stock has fallen by 37.15%, while the benchmark Sensex has only decreased by 6.83% during the same period, indicating a substantial underperformance relative to the market.<BR><BR>Today's trading activity shows that the stock has underperformed its sector by 5.42% and has experienced a trend reversal after two consecutive days of gains. The stock reached an intraday low of Rs 34.41, which is a 5.7% drop from the previous price. Additionally, the weighted average price indicates that more volume was traded closer to this low price, suggesting a lack of buying interest at higher levels.<BR><BR>The moving averages reveal that Gujarat Terce Laboratories Ltd is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, further indicating a bearish trend. Furthermore, there has been a significant decline in investor participation, with delivery volume dropping by 79.53% compared to the 5-day average. This lack of liquidity, combined with the overall negative performance metrics, contributes to the stock's current downward trajectory.

Which are the latest news on Guj. Terce Labs.?

How big is Guj. Terce Labs.?

As of 10th June, Gujarat Terce Laboratories Ltd has a market capitalization of 28.00 Cr, with recent net sales of 32.25 Cr and a net profit of 1.59 Cr. The company has shareholder's funds of 6.48 Cr and total assets of 22.39 Cr.

As of 10th June, Gujarat Terce Laboratories Ltd has a market capitalization of 28.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 32.25 Cr and a Net Profit of 1.59 Cr.<BR><BR>For the latest annual period ending in March 2025, the company has Shareholder's Funds amounting to 6.48 Cr and Total Assets of 22.39 Cr.

Who are in the management team of Guj. Terce Labs.?

The management team of Guj. Terce Labs includes Chairman Natwarbhai P Prajapati, Managing Director & CEO Aalap Prajapati, Whole-time Director Amrutbhai P Prajapati, and four Independent Directors: Chhayaben Ashwinbhai Shah, Viplav Suryakantbhai Khamar, Surendra Kumar Sharma, and Navinchandra Patel. They oversee the company's operations and strategic direction.

The management team of Guj. Terce Labs includes the following individuals:<BR><BR>1. **Natwarbhai P Prajapati** - Chairman & Whole-time Director<BR>2. **Aalap Prajapati** - Managing Director & CEO<BR>3. **Amrutbhai P Prajapati** - Whole-time Director<BR>4. **Chhayaben Ashwinbhai Shah** - Independent Director<BR>5. **Viplav Suryakantbhai Khamar** - Independent Director<BR>6. **Surendra Kumar Sharma** - Independent Director<BR>7. **Navinchandra Patel** - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Guj. Terce Labs.?

Peers of Guj. Terce Labs. include Lasa Supergeneri, Roopa Industries, Chandra Bhagat, Medi Caps, Welcure Drugs, Shree Ganesh Bio, Ishita Drugs, Venmax Drugs, Centuple Global, and Medicamen Organ. Guj. Terce Labs. has a 1-year return of -35.72%, better than Lasa Supergeneri's -44.40% but worse than Centuple Global's 105.84%.

Peers: The peers of Guj. Terce Labs. are Lasa Supergeneri, Roopa Industries, Chandra Bhagat, Medi Caps, Welcure Drugs, Shree Ganesh Bio, Ishita Drugs, Venmax Drugs, Centuple Global, and Medicamen Organ.<BR><BR>Quality Snapshot: Below Average management risk is observed at Lasa Supergeneri, Roopa Industries, Chandra Bhagat, Medi Caps, Welcure Drugs, Guj. Terce Labs., Shree Ganesh Bio, Ishita Drugs, Venmax Drugs, and Medicamen Organ. Average management risk is found at Welcure Drugs, while Good management risk is noted at Centuple Global. Growth is Excellent at Roopa Industries, while Below Average growth is seen at Lasa Supergeneri, Chandra Bhagat, Medi Caps, Guj. Terce Labs., Shree Ganesh Bio, Ishita Drugs, and Medicamen Organ. Average growth is observed at Venmax Drugs, while Good growth is noted at Centuple Global. Capital Structure is Average at Lasa Supergeneri, Guj. Terce Labs., and Medicamen Organ, Good at Medi Caps, Welcure Drugs, Shree Ganesh Bio, Ishita Drugs, and Centuple Global, and Below Average at Roopa Industries, Chandra Bhagat, and Venmax Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centuple Global at 105.84%, while the lowest is Lasa Supergeneri at -44.40%. Guj. Terce Labs. has a 1-year return of -35.72%, which is better than Lasa Supergeneri but worse than Centuple Global. Additionally, the six-month return is negative for Lasa Supergeneri, Medi Caps, Welcure Drugs, and Centuple Global.

What does Guj. Terce Labs. do?

Gujarat Terce Laboratories Ltd is a micro-cap pharmaceutical manufacturer established in 1985, specializing in oral solid dosages. As of March 2026, it reported net sales of 11 Cr and a market cap of INR 28 Cr.

Overview:<BR>Gujarat Terce Laboratories Ltd is a trusted manufacturer of high-quality medications in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>History:<BR>Incorporated in 1985, Gujarat Terce Laboratories has maintained its status as a reliable producer of oral solid dosages. The latest reported quarterly results indicate net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 11 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 28 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 11.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.30 <BR>Return on Equity: 25.13% <BR>Price to Book: 2.80 <BR><BR>Contact Details:<BR>Address: 122/2 Ravi Estate, Bileshwarpura Chhatral Gandhinagar Gujarat : 382729 <BR>Tel: 91-079-6663 3706 <BR>Email: ho@gujaratterce.com <BR>Website: http://www.gujaratterce.com

Should I buy, sell or hold Gujarat Terce Laboratories Ltd?

When is the next results date for Gujarat Terce Laboratories Ltd?

The next results date for Gujarat Terce Laboratories Ltd is 29 May 2026.

The next results date for Gujarat Terce Laboratories Ltd is scheduled for 29 May 2026.

Are Gujarat Terce Laboratories Ltd latest results good or bad?

Gujarat Terce Laboratories Ltd's latest results are poor, with a significant drop in operating margin from 16.40% to 5.33% and a 71.88% decline in net profit compared to the previous quarter. The company's low Mojo Score of 21 and "Strong Sell" rating indicate serious operational and financial challenges.

Gujarat Terce Laboratories Ltd's latest results indicate significant challenges for the company. The operating margin has collapsed from 16.40% in the previous quarter to just 5.33%, which raises serious concerns about cost management and operational efficiency. Additionally, the net profit for Q2 FY26 has dropped by a staggering 71.88% compared to the previous quarter, falling to ₹0.45 crore.<BR><BR>While there was a year-on-year growth of 21.62% in net profit compared to Q2 FY25, the overall financial performance is overshadowed by the sharp decline in profitability and the dramatic margin compression. The company's Mojo Score is only 21 out of 100, and it carries a "Strong Sell" rating, reflecting a lack of investor confidence and serious operational distress.<BR><BR>Overall, the results can be characterized as poor, with the company facing significant operational and financial hurdles that need to be addressed to restore stability and investor trust.

How has been the historical performance of Guj. Terce Labs.?

Guj. Terce Labs has experienced a decline in net sales and profitability over the past three years, culminating in a loss of -2.52 Cr in the most recent fiscal year, with significant decreases in revenue and operating profit. The company's financial metrics indicate ongoing challenges in generating cash from core operations.

Answer:<BR>The historical performance of Guj. Terce Labs shows a decline in net sales and profitability over the past three years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2021, Guj. Terce Labs reported net sales of 25.18 Cr, a significant decrease from 37.54 Cr in March 2020 and 31.03 Cr in March 2019. The total operating income mirrored this trend, remaining at 25.18 Cr in March 2021, down from 37.54 Cr in March 2020. The company's total expenditure, excluding depreciation, was 27.94 Cr in March 2021, which also saw a decline from 36.86 Cr in March 2020. This resulted in an operating profit (PBDIT) of -1.96 Cr in March 2021, a stark contrast to the positive figures of 0.97 Cr in March 2020 and 0.80 Cr in March 2019. Consequently, the profit before tax was -2.53 Cr in March 2021, compared to 0.44 Cr in March 2020 and 0.35 Cr in March 2019, leading to a profit after tax of -2.52 Cr in March 2021, down from 0.28 Cr in March 2020 and 0.43 Cr in March 2019. The earnings per share (EPS) reflected this downturn, falling to -3.4 in March 2021 from 0.38 in March 2020 and 0.58 in March 2019. The company's total liabilities decreased to 21.70 Cr in March 2021 from 22.34 Cr in March 2020, while total assets also declined to 21.70 Cr from 22.34 Cr in the same period. Cash flow from operating activities was stagnant at 0.00 Cr in March 2021, indicating challenges in generating cash from core operations. Overall, the financial metrics indicate a concerning trend for Guj. Terce Labs, with declining revenues and increasing losses.

Is Guj. Terce Labs. overvalued or undervalued?

As of November 17, 2025, Guj. Terce Labs. is considered very expensive and overvalued, with a PE ratio of -32.23 and poor stock performance, significantly lagging behind peers like Sun Pharma and Divi's Lab.

As of 17 November 2025, the valuation grade for Guj. Terce Labs. has moved from expensive to very expensive. This indicates a significant deterioration in its valuation outlook, suggesting that the company is overvalued. The key ratios highlight this concern, with a PE ratio of -32.23, a Price to Book Value of 4.39, and an EV to EBITDA of 7.59, all of which signal potential overvaluation when compared to industry norms.<BR><BR>In comparison to its peers, Guj. Terce Labs. stands out unfavorably; for instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Divi's Lab shows a PE of 69.78 and an EV to EBITDA of 52.44. These comparisons further reinforce the notion that Guj. Terce Labs. is not only overvalued but also lagging behind its competitors in terms of financial performance. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -47.76%, contrasting sharply with the Sensex's positive return of 8.72%.

Who are the top shareholders of the Guj. Terce Labs.?

The top shareholders of Guj. Terce Labs are Abundant Trade Link Private Limited with 14.5% and public shareholder Sagar Saxena with 1.39%. Individual investors hold a total of 59.34%, with no current institutional holdings.

The top shareholders of Guj. Terce Labs include Abundant Trade Link Private Limited, which holds the highest promoter stake at 14.5%. Additionally, the highest public shareholder is Sagar Saxena, with a holding of 1.39%. Overall, individual investors collectively hold a significant 59.34% of the company's shares. There are no institutional holdings from mutual funds or foreign institutional investors at this time.

What is the technical trend for Guj. Terce Labs.?

As of May 6, 2025, Guj. Terce Labs has shifted to a bearish technical trend, indicated by a bearish MACD, moving averages, and KST, with the stock trading at 54.99 and showing a significant year-to-date decline compared to the Sensex.

As of 6 May 2025, the technical trend for Guj. Terce Labs has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Additionally, both the Bollinger Bands and Dow Theory indicate a mildly bearish trend on the weekly and monthly time frames. The stock is currently trading at 54.99, showing a significant decline year-to-date compared to the Sensex.

Has Guj. Terce Labs. declared dividend?

No Dividend History Available